Literature DB >> 20573851

Sorafenib-induced erythema multiforme for metastatic renal cell carcinoma.

M Kodaira1, S Takahashi2, K Takeuchi3, T Yuasa1, T Saotome1, J Yonese4, I Fukui4, K Hatake1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20573851     DOI： 10.1093/annonc/mdq299

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  6 in total

1.  Sorafenib-Induced Eruption Mimicking Erythema Multiforme.

Authors:  Dominique C Pichard; Adela R Cardones; Emily Y Chu; William L Dahut; Heidi H Kong
Journal:  JAMA Dermatol       Date:  2016-02       Impact factor: 10.282

2.  Erythema multiforme after treatment with sorafenib.

Authors:  Aaminah Faheem Azhar; Rachael Camille Saporito; Jordan Jamerson
Journal:  Proc (Bayl Univ Med Cent)       Date:  2021-03-08

3.  Sorafenib induces delayed-onset cutaneous hypersensitivity: a case series.

Authors:  Kyoung Hee Sohn; Soo Yeon Oh; Kyung Whan Lim; Mi Yeong Kim; Suh Young Lee; Hye Ryun Kang
Journal:  Allergy Asthma Immunol Res       Date:  2014-03-05       Impact factor: 5.764

4.  Alectinib-Induced Erythema Multiforme and Successful Rechallenge with Alectinib in a Patient with Anaplastic Lymphoma Kinase-Rearranged Lung Cancer.

Authors:  Tatsuo Kimura; Junko Sowa-Osako; Toshiyuki Nakai; Ayako Ohyama; Tomoya Kawaguchi; Daisuke Tsuruta; Masahiko Ohsawa; Kazuto Hirata
Journal:  Case Rep Oncol       Date:  2016-12-08

5.  Erythema multiforme major induced by sunitinib for metastatic renal cell carcinoma.

Authors:  Daisuke Watanabe; Akemi Yamashita; Tadaaki Minowa; Kunihisa Miura; Akio Mizushima
Journal:  Urol Case Rep       Date:  2019-06-04

6.  Case Report: Severe rash/desquamation induced by sorafenib in an uHCC patient and its clinical management.

Authors:  Yan Lin; Ping-Yu Liu
Journal:  Front Pharmacol       Date:  2022-09-13       Impact factor: 5.988
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.